Table 5.

Association of the CTI with dyslipidemia incidence across physical activity levels.

Physical activity	Variable	Number of events, n	Model 1			Model 2			Model 3
			HR	95% CI	p	HR	95% CI	p	HR	95% CI	p
Light	CTI (per 1-unit)	634	1.11	1.02-1.20	0.03	1.10	1.01-1.19	0.04	1.11	1.02-1.18	0.04
	Q1 (Ref)	122
	Q2	141	1.03	0.87-1.22	0.72	1.02	0.86-1.21	0.76	1.03	0.85-1.22	0.77
	Q3	170	1.07	0.91-1.27	0.33	1.06	0.90-1.26	0.36	1.04	0.87-1.23	0.36
	Q4	201	1.25	1.05-1.49	0.02	1.23	1.04-1.47	0.03	1.21	1.02-1.44	0.03
	P for trend				0.02			0.03			0.03
Moderate	CTI (per 1-unit)	982	1.12	1.03-1.21	0.01	1.11	1.02-1.20	0.02	1.11	1.02-1.17	0.02
	Q1 (Ref)	163
	Q2	218	1.01	0.86-1.18	0.90	1.01	0.86-1.18	0.91	1.01	0.84-1.17	0.93
	Q3	290	1.09	0.93-1.27	0.25	1.08	0.92-1.26	0.28	1.06	0.92-1.24	0.31
	Q4	311	1.28	1.09-1.50	0.01	1.26	1.07-1.49	0.01	1.24	1.05-1.46	0.02
	P for trend				0.01			0.02			0.02
Vigorous	CTI (per 1-unit)	395	1.30	1.08-1.56	0.01	1.29	1.07-1.55	0.01	1.26	1.05-1.53	0.02
	Q1 (Ref)	95
	Q2	89	1.18	0.84-1.65	0.33	1.16	0.83-1.62	0.35	1.14	0.81-1.62	0.34
	Q3	82	1.25	0.90-1.74	0.15	1.23	0.88-1.72	0.18	1.21	0.86-1.72	0.20
	Q4	129	1.49	1.11-2.01	0.01	1.47	1.09-1.98	0.02	1.44	1.07-1.94	0.02
	P for trend				0.01			0.02			0.02

HR = hazard ratio; CI = confidence interval. Q1 denotes the lowest quartile, which served as the reference category. Model 1 included no covariate adjustment; Model 2 was adjusted for demographic and lifestyle characteristics (sex, age, residence, marital status, education, smoking, and alcohol consumption); and Model 3 additionally accounted for comorbid conditions such as chronic diseases, arthritis, liver disease, asthma, kidney disease, and gastrointestinal disorders, as well as the use of anti-diabetic medication, anti-hypertensive medication, and lipid-lowering medication as covariates. The p for trend was estimated by modeling the median value of each quartile as a continuous variable in the Cox regression model. Statistical significance was defined as a two-sided p < 0.05.